Brief: Bright Minds To Announce Topline Results For BMB-101 Phase 2 Trial In On Jan 6
05/01/2026 22:20
Jan 5 (Reuters) - Bright Minds Biosciences Inc DRUG.CD: BRIGHT MINDS TO ANNOUNCE TOPLINE RESULTS FOR BMB-101 PHASE 2 TRIAL IN ABSENCE SEIZURES AND DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES ON TUESDAY, JANUARY 6, 2026 Source text: ID:nGNX4BwmqF Further company coverage: DRUG.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bright Minds Biosciences
See all newsBright Minds Biosciences slips after increased $175 mln stock sale
Brief: Bright Minds Biosciences Announces Pricing Of Upsized US$175 Million Public Offering Of Common Stock At $90.00 Per Share
Bright Minds Biosciences falls after $100 mln equity offering launched
Brief: Bright Minds To Announce Topline Results For BMB-101 Phase 2 Trial In On Jan 6
Brief: Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders